Pharyngeal carriage rates of Neisseria meningitidis in health care professionals at a tertiary university pediatric hospital.
Adolescent
Adult
Austria
/ epidemiology
Carrier State
/ epidemiology
Cross-Sectional Studies
Female
Health Personnel
Hospitals, Pediatric
Humans
Male
Meningococcal Infections
/ epidemiology
Middle Aged
Neisseria meningitidis
/ genetics
Occupational Diseases
/ epidemiology
Pharynx
/ microbiology
Prevalence
Surveys and Questionnaires
Universities
Young Adult
Meningococcal carriage
Neisseria meningitidis
Pediatric health care professionals
Pediatric hospital
Pharyngeal carriage rates
Journal
European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology
ISSN: 1435-4373
Titre abrégé: Eur J Clin Microbiol Infect Dis
Pays: Germany
ID NLM: 8804297
Informations de publication
Date de publication:
Sep 2020
Sep 2020
Historique:
received:
02
01
2020
accepted:
01
04
2020
pubmed:
26
4
2020
medline:
2
4
2021
entrez:
26
4
2020
Statut:
ppublish
Résumé
Pharyngeal carriage is the reservoir for Neisseria meningitidis in the population and the first step in disease transmission. Especially in young infants and adolescents, N. meningitidis can cause serious invasive infection with high fatality rates and high rates of long-term sequelae among survivors. The aim of this study was to determine N. meningitidis colonization rates in asymptomatic health care professionals at a tertiary university pediatric hospital and to identify risk factors for carriage. This cross-sectional meningococcal carriage survey was conducted between April and October 2018 at the Medical University of Vienna. Individuals working as nurses, pediatricians, or medical students were enrolled. Oropharyngeal swabs were directly plated onto selective agar plates and conventional culture was used for bacterial identification. Meningococcal isolates were further characterized using whole-genome sequencing. A total of 437 oropharyngeal specimens were collected. Overall, meningococcal carriage prevalence was 1.14% (5/437), with 0.7% (3/437) for capsular genotype B, and 0.5% (2/437) for capsular genotype W. Mean age of carriers was significantly lower than of non-carriers (24.2 vs. 35.8; p = 0.004). The highest carriage rate of 4.4% (4/91) was found in the age group 18-25. Carriage was negatively associated with age and timespan working in pediatrics. This is the first study evaluating the prevalence of Neisseria meningitidis carriage in health care professionals working in Pediatrics and Adolescent Medicine. Carriage was in general lower than expected for all age groups, implicating a low risk of meningococcal transmission via this population.
Identifiants
pubmed: 32333221
doi: 10.1007/s10096-020-03894-9
pii: 10.1007/s10096-020-03894-9
pmc: PMC7427699
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1703-1709Subventions
Organisme : Pfizer Corporation Austria Gesellschaft m.b.H.
ID : WI234668
Références
Int J Infect Dis. 2018 Aug;73:109-117
pubmed: 29997031
Lancet. 2000 Nov 11;356(9242):1654-5
pubmed: 11089828
Rev Argent Microbiol. 2015 Oct-Dec;47(4):322-7
pubmed: 26572958
Vaccine. 2018 Jan 2;36(1):29-35
pubmed: 29183735
PLoS One. 2019 Feb 8;14(2):e0212052
pubmed: 30735539
J Infect. 1983 Mar;6(2):147-56
pubmed: 6875288
Clin Microbiol Infect. 1996;2(2):145-146
pubmed: 11866834
PLoS One. 2016 Dec 1;11(12):e0167404
pubmed: 27907129
Lancet Glob Health. 2016 Dec;4(12):e989-e995
pubmed: 27855873
Crit Care. 2004 Feb;8(1):46-53
pubmed: 14975045
Hum Vaccin Immunother. 2017 May 4;13(5):1182-1189
pubmed: 28140784
J Med Microbiol. 2004 Sep;53(Pt 9):821-832
pubmed: 15314188
FEMS Microbiol Rev. 2007 Jan;31(1):52-63
pubmed: 17233635
J Infect. 2015 Jul;71(1):43-52
pubmed: 25709085
J Clin Microbiol. 2011 Feb;49(2):506-12
pubmed: 21123536
Clin Infect Dis. 2014 Nov 1;59(9):1216-21
pubmed: 25069869
Lancet. 2002 May 25;359(9320):1829-31
pubmed: 12044380
JAMA. 2001 Aug 8;286(6):688-93
pubmed: 11495618
J Clin Microbiol. 1995 Dec;33(12):3133-7
pubmed: 8586688
Lancet. 2007 Jun 30;369(9580):2196-2210
pubmed: 17604802
Acta Biomed. 2017 Oct 23;88(3):337-351
pubmed: 29083344
BMJ. 1999 Oct 30;319(7218):1147-8
pubmed: 10541486
J Antimicrob Chemother. 1988 Apr;21(4):489-96
pubmed: 3132442
J Clin Microbiol. 2012 Feb;50(2):264-73
pubmed: 22135261
Vaccine. 2012 May 30;30 Suppl 2:B3-9
pubmed: 22607896
J Infect. 2009 Feb;58(2):103-7
pubmed: 19167762
Epidemiol Infect. 2003 Apr;130(2):201-5
pubmed: 12729188
BMC Infect Dis. 2014 Dec 04;14:663
pubmed: 25472422
J Korean Med Sci. 2017 Jul;32(7):1111-1117
pubmed: 28581267
Lancet. 2014 Dec 13;384(9960):2123-31
pubmed: 25145775
Lancet Infect Dis. 2010 Dec;10(12):853-61
pubmed: 21075057
Vaccine. 2009 Jun 24;27 Suppl 2:B64-70
pubmed: 19464092
BMC Infect Dis. 2019 Jan 8;19(1):29
pubmed: 30621624
Euro Surveill. 2019 Apr;24(14):
pubmed: 30968827
Emerg Infect Dis. 2006 Jun;12(6):950-7
pubmed: 16707051
J Clin Microbiol. 2002 Jan;40(1):75-9
pubmed: 11773095
J Clin Microbiol. 2016 Nov;54(11):2743-2748
pubmed: 27582517
Curr Neurol Neurosci Rep. 2015 Mar;15(3):2
pubmed: 25637287
Vaccine. 2017 Apr 25;35(18):2473-2478
pubmed: 28343777
Expert Rev Anti Infect Ther. 2011 Sep;9(9):761-74
pubmed: 21905785
Hum Vaccin Immunother. 2019;15(4):987-994
pubmed: 30513251